SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Jun 13, 2019
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: June 13, 2019 · CIK: 0001390478 · Accession: 0001144204-19-030766
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231723
Letter
Via EDGAR United States Securities and Exchange Commission Division of Corporate Finance Office of Healthcare & Insurance Re: SELLAS Life Sciences, Inc. Registration Statement on Form S-1 File No. 333-231723 Acceleration Request
Dear Ms. Bednarowski,
With respect to the above-referenced Registration Statement on Form S-1 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of SELLAS Life Sciences Group, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Thursday, June 13, 2019, at 4:30 p.m. Eastern Time, or as soon as practicable thereafter.
In connection with the foregoing request, the Company acknowledges the following:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call Daniel A. Bagliebter, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (212) 692-6856 with any comments or questions regarding the Registration Statement.
Very truly yours,
SELLAS Life Sciences Group, Inc.
Show Raw Text
CORRESP
1
filename1.htm
SELLAS Life Sciences Group, Inc.
15 West 38th St., 10th
Floor
New York, New York 10018
June 13,
2019
Via
EDGAR
Sonia Bednarowski
United States Securities and Exchange Commission
Division of Corporate Finance
Office of Healthcare & Insurance
100 F Street, N.E.
Washington, D.C. 20549
Re: SELLAS Life
Sciences, Inc.
Registration Statement on Form S-1
File No. 333-231723
Acceleration Request
Dear Ms. Bednarowski,
With respect to the
above-referenced Registration Statement on Form S-1 (the “Registration Statement”), and pursuant to Rule 461 of Regulation
C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of SELLAS
Life Sciences Group, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”)
accelerate the effective date of the Registration Statement to Thursday, June 13, 2019, at 4:30 p.m. Eastern Time, or as soon
as practicable thereafter.
In connection with
the foregoing request, the Company acknowledges the following:
· should
the Commission or the staff, acting pursuant to delegated authority, declare the filing
effective, it does not foreclose the Commission from taking any action with respect to
the filing;
· the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the
adequacy and accuracy of the disclosure in the filing; and
· the
Company may not assert staff comments and the declaration of effectiveness as a defense
in any proceeding initiated by the Commission or any person under the federal securities
laws of the United States.
The cooperation of
the staff in meeting the timetable described above is very much appreciated.
Please call Daniel
A. Bagliebter, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (212) 692-6856 with any comments
or questions regarding the Registration Statement.
Very truly yours,
SELLAS Life Sciences Group, Inc.
/s/ Angelos
M. Stergiou
By: Angelos M. Stergiou, M.D., Sc.D., h.c.
Its: President and Chief Executive Officer
cc: Daniel A. Bagliebter,
Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.